---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000111"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:20:10.526471+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine monetizes Vertex license fees for $57M upfront from DRI Healthcare Trust

## Summary
- Upfront cash payment of $57M from DRI subsidiary for up to 100% of future annual license fees ($5M-$40M/year) and a mid-double-digit % of $50M contingent payment under Vertex Cas9 license.
- Non-dilutive capital to fund pipeline development and strategic priorities; Editas retains 2024 fixed fees and a mid-single-digit million milestone payment from Vertex.
- Purchase agreement has no financial covenants; potential liquidated damages or termination fees of one-to-two times the upfront payment under specified conditions.
- Vertex license (Dec 2023) covers Cas9 technology for ex vivo BCL11A gene editing in sickle cell disease and beta thalassemia, including CASGEVY.

## SEC filing metadata
- accession: 0001650664-24-000111
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000111/0001650664-24-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000111/edit-20241003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000111
- JSON: https://secwatch.observer/filing/0001650664-24-000111.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.